From our now wiped by the cloud provider unmuteit.com 2023 post re Musk backed german mRNA vaccine maker CureVac in 2020 when he announced via Twitter that Tesla was building "RNA microfactories" for CureVac, a German biotech company focused on developing mRNA-based vaccines, including one for COVID-19. These "microfactories" were described as portable, automated mRNA production units, which Musk referred to as "RNA printers." intended to churn out mRNA vaccine candidates and potentially other mRNA-based therapies based on the recipe fed into the machines. This initiative was part of a broader effort to leverage mRNA technology for rapid vaccine production during the COVID-19 pandemic, aiming to make vaccine manufacturing more flexible and decentralized.

Tesla, through its German subsidiary Tesla Grohmann Automation, was involved in developing these microfactories. However, the specifics of their progress, completion, or the actual deployment of these units are not detailed in the provided sources beyond the initial announcement.

The question remains for Musk about the status of mRNA microfactories project and whether the Tesla microfactories specifically influenced or were integrated into CureVac's or any other vaccine maker broader vaccine production strategy. the time frame of the sources (all from 2020), no public information from musk how far this initiative progressed or any other entity or company collaboration is available.

In summary, while Tesla announced its involvement in building mRNA micro-factories for CureVac in 2020, there's no detailed follow-up in the provided sources about their operational success, scale of implementation, or whether this project continued beyond the initial stages.

In the meantime, at least recently Musk backed german CureVac in 2020 ( any public comment will be of value on current status of mRNA micro factories and possible collaborations with any vaccine /gene therapy makers) Announced Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine in 2023 . alpha 5/18/2023, 10:52:48 PM

Curevac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK https://www.curevac.com/wp-content/uploads/2023/05/20230508-Curevac-Announces-Dosing-of-First-Participant-in-Phase-1-2-Flu-Study.pdf

In September 2024 cutback reports about phase 2 “Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement”

On another note, trumps VP JD Vance’s Narya capital stake with investments in healthcare, life sciences, aerospace, Narya Capital Investments include:

AmplifyBio: A company focused on among many others things on LNP , gene therapy, mRNA manufacturing for a broad range of drug modalities, including small molecule, cell and gene therapies, mRNA, and other biologics. commercial drug discovery, particularly in areas like vaccine technologies and drug development. Narya was one of several investors in a $200 million funding round. Kriya Therapeutics Involved in the development of gene therapies. Narya participated in a $100 million Series B financing, though not as the lead investor but alongside others like Patient Square Capital.

Aerospace

True Anomaly: An aerospace company that Narya invested in through two funding rounds. True Anomaly won a $30 million government contract from the US Space Force.

• Chapter: A Medicare advisor company where Narya led a $17M Series A funding round.
• ValueBase: A property valuation software with applications in government sectors. Narya Capital Fund I stake is reported to be worth between $500,001 and $1 million.

Last but not the least is Vivek ramaswamy with his GENEVANT from Genevant’s site “ our proprietary advantages, LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues. Our LNP platform, the delivery technology behind the first and only siRNA-LNP product to achieve regulatory approval (Alnylam’s ONPATTRO®), also enables a wide array of mRNA-based applications, including vaccines, therapeutic protein production, and gene editing”